In aseptic processing of sterile doxorubicin hydrochloride powder for intravenous use, the API is compounded into a bulk solution at a target concentration of 5 mg/mL doxorubicin hydrochloride in Water for Injection, with lactose monohydrate added as a lyoprotectant and bulking agent at a representative API-to-lactose ratio of 1:5 (w/w) for a 10 mg/vial presentation. The solution pH is adjusted with dilute hydrochloric acid or sodium hydroxide to the range specified in the pharmacopoeial monograph, then passed through a sterilizing-grade 0.22 µm double-layer filter assembly containing polyvinylidene difluoride or polyethersulfone membranes. The filtrate is filled into USP Type I borosilicate glass vials under Grade A laminar air flow within an ISO Class 5 cleanroom as required by EU GMP Annex 1 and FDA 21 CFR 211.42. Vials are partially stoppered with halobutyl elastomeric closures and transferred to a shelf freeze dryer. The lyophilization cycle is developed using freeze-drying microscopy and differential scanning calorimetry to identify the collapse temperature of the formulation; primary drying is conducted below the collapse temperature, with secondary drying bringing the product to a residual moisture content controlled by Karl Fischer titration per USP <921>.

Production-scale lyophilization failures for doxorubicin hydrochloride powder include cake collapse, meltback, glass vial fogging, and high residual moisture. These failures are commonly linked to exceeding the collapse temperature during primary drying, insufficient vacuum pull, or premature stoppering before secondary drying completion. Lyophilizer shelf temperature is therefore maintained at least 2–5°C below the measured collapse temperature of the formulated bulk solution, with chamber pressure controlled between 50 mTorr and 150 mTorr during primary drying depending on product height and vial fill volume. Stoppering occurs under vacuum or partial nitrogen pressure using ISO 5 conditions. Cake appearance is inspected on line for shrinkage, cracking, and discoloration; reconstitution time is measured on production batches using a fixed volume of 0.9% sodium chloride injection or Sterile Water for Injection. Batch-to-batch variance in cake integrity has been traced to freezing ramp rate differences and to vial misalignment on the shelf, both of which are controlled through validated freeze-dryer load patterns and thermocouple mapping.

Remote loading of doxorubicin hydrochloride into pre-formed pegylated liposomes via an ammonium sulfate gradient begins with a lipid phase composed of hydrogenated soy phosphatidylcholine, cholesterol, and N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine. The lipids are dissolved in ethanol, hydrated with an ammonium sulfate solution, and extruded through polycarbonate membranes with a pore size of 80 nm using a high-pressure extruder to obtain unilamellar vesicles. The external ammonium sulfate is removed by diafiltration or tangential flow filtration, and doxorubicin hydrochloride is added to the extruded liposome suspension. At an elevated temperature of approximately 60°C, the drug crosses the lipid bilayer and precipitates inside the liposome as a doxorubicin sulfate salt, a process that routinely produces encapsulation efficiencies above 90% when the lipid-to-drug molar ratio and ammonium sulfate gradient are optimized. The liposome suspension is then concentrated, buffer-exchanged into a histidine-sucrose stabilizer system, passed through a 0.22 µm filter, and filled aseptically into USP Type I glass vials. The terminal product is a ready-to-dilute dispersion for intravenous infusion, with a phospholipid concentration of approximately 16 mg/mL and a doxorubicin content of 2 mg/mL in published formulations; the exact composition is governed by the specific regulatory file.

Quality control for liposomal doxorubicin requires particle size analysis by dynamic light scattering per ISO 22412, with a Z-average diameter typically 80–100 nm and a polydispersity index below 0.1. Zeta potential measured by electrophoretic light scattering is typically negative due to the PEGylated surface. Free drug content is separated by ultrafiltration, size-exclusion chromatography, or solid-phase extraction and quantified by HPLC; free doxorubicin is generally limited to ≤10% of total doxorubicin in release specifications. In vitro drug release is performed using dialysis-based methods under sink conditions at 37°C; published data for this specific configuration is limited, and the method must be validated for the product-specific lipid composition and drug-loading protocol. Terminal sterilization is not applied to liposomal doxorubicin because the liposome structure is heat-labile; aseptic processing through sterilizing-grade filtration is mandatory. Storage is typically at 2–8°C with protection from light, and freeze-thaw cycling must be avoided because it causes vesicle fusion, drug leakage, and particle size growth.

Ready-to-use doxorubicin hydrochloride injection at 2 mg/mL follows a simplified aseptic fill route

Ready-to-use doxorubicin hydrochloride injection at 2 mg/mL is manufactured by dissolving the API in Water for Injection with sodium chloride for isotonicity. pH adjustment is made with dilute hydrochloric acid or sodium hydroxide to the pharmacopoeial monograph range, and the bulk solution is passed through a sterilizing-grade 0.22 µm filter. Filling is performed on a high-speed aseptic filling line equipped with rotary piston pumps or peristaltic pumps into USP Type I glass vials or polypropylene ampoules under Grade A air supply. The terminally filled containers are inspected for visible particulate matter using automated light obscuration or manual panel inspection. The solution is photosensitive, so secondary packaging includes an overwrap or carton that limits light exposure. Storage at 2–8°C is standard for extended stability; brief room-temperature excursions are managed through stability data in the regulatory file. This presentation removes hospital reconstitution steps but increases shipment weight and requires cold-chain distribution monitoring.

When Cytotoxic Injectable Compounding Requires Closed-System Transfer Devices and Stability-Limited Hang Times

Reconstitution and dilution of doxorubicin hydrochloride for patient-specific intravenous administration are performed in an ISO Class 5 biological safety cabinet or compounding aseptic isolator compliant with USP <797> and USP <800>. Personnel are required to use closed-system transfer devices, double chemotherapy gloves, and impermeable gowns because doxorubicin is classified as a hazardous drug by the NIOSH List of Antineoplastic and Other Hazardous Drugs. The lyophilized powder is reconstituted with 0.9% sodium chloride injection or Sterile Water for Injection to a nominal concentration of 2 mg/mL; the resulting solution is further diluted into polyolefin infusion bags with 0.9% sodium chloride injection or 5% dextrose injection. Published stability data support limited beyond-use dating for infusions at controlled room temperature; long-term storage without refrigeration is not recommended. The terminal product is a patient-specific intravenous infusion requiring label documentation of total dose, final concentration, diluent identity, beyond-use date, and administration rate. Incompatibilities with heparin-containing flush solutions and certain antineoplastic admixtures must be assessed against the specific infusion protocol.

Direct compression of doxorubicin hydrochloride in oral solid dosage forms is not an approved commercial route in major regulatory jurisdictions because doxorubicin undergoes extensive P-glycoprotein-mediated efflux in the intestinal epithelium and first-pass metabolism, resulting in low oral bioavailability. Published absolute oral bioavailability in clinical studies is generally below 5%, and no pharmacopoeial monograph exists for an oral tablet or capsule presentation; therefore, formulation development is confined to investigational protocols and requires justification of the chosen bioavailability-enhancement strategy. If a tablet or capsule is formulated, the blend is typically prepared by geometric dilution of the active substance with microcrystalline cellulose, lactose monohydrate, and crospovidone in a tumbling mixer; magnesium stearate is added as a lubricant at 0.5–1.0% (w/w) in the final phase. The API can be dissolved in a hydroalcoholic binder solution for wet granulation, but the solvent must be removed to below the ICH Q3C residual solvent limit for the selected alcohol. Compression is performed on a rotary tablet press equipped with containment isolators, and tablet specifications include content uniformity per USP <905>, dissolution testing per USP <711>, and hardness testing. Due to the cytotoxic potency of the API, wash-in-place systems and validated decontamination protocols are required.

Encapsulation of doxorubicin hydrochloride in hard gelatin or HPMC capsules uses dosator or tamping-pin filling machines with gravimetric control for low-dose fill accuracy. The powder blend must exhibit acceptable flowability and compactibility for automated capsule filling; glidants such as colloidal silicon dioxide may be added at levels below 1.0% w/w. Terminal product specifications for an investigational oral capsule include content uniformity, dissolution, related substances, and microbial limits. The dissolution method is developed with USP <711> apparatus 2 at 37°C, using a dissolution medium selected to discriminate formulation variables without exceeding sink conditions for the poorly soluble free base. Published data for this specific configuration is limited, so acceptance criteria must be derived from batch data and in vivo correlation studies.

What Granulation Technologies Preserve API Potency in Oral Granules?

Fluid-bed granulation of doxorubicin hydrochloride for oral sachet or granule presentations is constrained by the need to maintain API uniformity at low mass fractions while controlling airborne particulates that are genotoxic and teratogenic. Top-spray fluid-bed granulation using a Glatt GPCG or equivalent is the most commonly evaluated process because it integrates blending, spray agglomeration, and drying in a single closed vessel. A typical binder solution contains hydroxypropyl methylcellulose or povidone in purified water; the binder is sprayed at a rate of 10–25 g/min per kilogram of batch charge, with inlet air temperature kept below 60°C to avoid thermal degradation of doxorubicin. The granulation end point is determined by loss-on-drying and by particle size analysis using sieve stacks; target granule size is between 150 µm and 500 µm for reproducible sachet filling. The dried granules are filled into polyester-aluminum-polyethylene sachet stock by an auger or volumetric filler. The terminal product is a single-dose granule for oral suspension, reconstituted with water before administration.

Compliance for oral granules includes ICH Q3D elemental impurity limits and residual solvent control per ICH Q3C. Process validation must demonstrate blend uniformity per applicable pharmacopoeial guidance, with special attention to the low-dose API distribution and segregation potential during sachet filling. Microbial limits for nonsterile oral dosage forms are set by the relevant pharmacopoeial monograph. Operator exposure is controlled through the use of downflow booths, closed material transfer, and validated decontamination procedures; airborne doxorubicin monitoring is performed by surface wipe sampling and air sampling using HPLC analysis. No terminal sterilization step is applied to oral granules because the final product is nonsterile, but bioburden control of raw materials and equipment is mandatory.